Compare AIRJW & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRJW | ICUCW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 16 | 17 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2021 |
| Metric | AIRJW | ICUCW |
|---|---|---|
| Price | $1.20 | $0.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 116.3K | 59.8K |
| Earning Date | 03-21-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.01 |
| 52 Week High | $1.87 | $0.08 |
| Indicator | AIRJW | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 73.76 | 44.43 |
| Support Level | $0.56 | $0.01 |
| Resistance Level | $1.87 | $0.04 |
| Average True Range (ATR) | 0.15 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 82.61 | 66.67 |
AirJoule Technologies Corp is an advance technology company whose purpose is to free the world from its water and energy constraints by delivering groundbreaking sorption technologies. The company platform technology, AirJoule, produces pure distilled water from air and, at commercial scale, will mitigate water scarcity through distributed water generation for businesses and consumers around the world. Its products are especially valuable for industrial users, which generate amounts of waste heat that can be used to power sorption technologies to produce low-cost pure distilled water and dehumidified air, two key inputs for a variety of industrial activities, including data centers and advance manufacturing. The Company operates as a single operating and reportable segment.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.